Table 2 Performance of antibody tests in diagnosing untreated celiac disease and monitoring treated celiac disease
Primary diagnosis of untreated celiac disease (Group A, n = 97) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
Sens | 95% CI | Spec | 95% CI | AUC | 95% CI | LR+ | 95% CI | LR- | 95% CI | |
Anti-tissue transglutaminase | ||||||||||
Eurospital IgA | 1.00 | 0.85 to 1.00 | 0.98 | 0.90 to 1.00 | 1.00 | 0.99 to 1.00 | 41.96 | 8.62 to 204.13 | 0.020 | 0.000 to 0.270 |
Inova IgG | 0.71 | 0.52 to 0.86 | 0.86 | 0.75 to 0.93 | 0.85 | 0.77 to 0.93 | 4.97 | 2.61 to 9.47 | 0.340 | 0.190 to 0.590 |
Anti-endomysial antibodies | ||||||||||
Orgentec IgA | 1 | 0.85 to 1.00 | 0.85 | 0.53 to 0.97 | - | - | 5.51 | 1.79 to 16.95 | 0.020 | 0.000 to 0.320 |
Antibodies against deamidated gliadin peptides | ||||||||||
Inova IgA | 0.93 | 0.76 to 0.99 | 0.94 | 0.85 to 0.98 | 0.97 | 0.94 to 1.00 | 14.63 | 5.63 to 37.96 | 0.080 | 0.020 to 0.290 |
Inova IgG | 0.97 | 0.83 to 1.00 | 0.95 | 0.87 to 0.99 | 0.99 | 0.98 to 1.00 | 20.32 | 6.72 to 61.43 | 0.034 | 0.000 to 0.230 |
Monitoring treated celiac disease (Group B, n = 53) | ||||||||||
Anti-tissue transglutaminase | ||||||||||
Eurospital IgA | 0.83 | 0.36 to 1.00 | 0.87 | 0.74 to 0.95 | 0.86 | 0.69 to 1.00 | 6.53 | 2.85 to 14.95 | 0.191 | 0.032 to 1.147 |
Inova IgG | 0.67 | 0.22 to 0.96 | 0.79 | 0.64 to 0.89 | 0.74 | 0.49 to 0.99 | 3.13 | 1.42 to 6.90 | 0.423 | 0.135 to 1.326 |
Anti-endomysial antibodies | ||||||||||
Orgentec IgA | 1.00 | 0.50 to 1.00 | 0.74 | 0.59 to 0.86 | 0.89 | 0.80 to 0.98 | 3.57 | 2.12 to 5.99 | 0.097 | 0.070 to 1.403 |
Antibodies against deamidated gliadin peptides | ||||||||||
Inova IgA | 0.67 | 0.22 to 0.96 | 0.66 | 0.51 to 0.79 | 0.61 | 0.38 to 0.84 | 1.96 | 0.98 to 3.91 | 0.505 | 0.160 to 1.596 |
Inova IgG | 0.83 | 0.36 to 1.00 | 0.77 | 0.62 to 0.88 | 0.88 | 0.76 to 0.99 | 3.56 | 1.90 to 6.68 | 0.218 | 0.036 to 1.311 |